Ads
related to: amerisourcebergen abc nyseCombination of great tools, asset classes, & low costs - Investopedia
Search results
Results from the WOW.Com Content Network
Financials as of September 30, 2023. [update] [1] Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale company and a contract research organization that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. [2]
AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
AmerisourceBergen now expects 2023 adjusted earnings in the range of $11.85 to $11.95 per share, compared with its prior forecast of $11.70 to $11.90 per share.
Let's see if AmerisourceBergen Corporation (ABC) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
AmerisourceBergen (ABC) possesses solid growth attributes, which could help it handily outperform the market. Is AmerisourceBergen (ABC) a Solid Growth Stock? 3 Reasons to Think "Yes" Skip to main ...
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.
AmerisourceBergen (ABC) registers strong growth in the Pharmaceutical Distribution segment and the World Courier business in Q4. AmerisourceBergen (ABC) Beats on Q4 Earnings, Issues '19 View Skip ...
Steven H. Collis (born 1961) is an American businessman, the chairman, president and chief executive officer (CEO) of Cencora, previously known as AmerisourceBergen. Early life. Collis was born in South Africa and attended the University of Witwatersrand, where he earned a Bachelor of Commerce. Collis is Jewish. Career
Ads
related to: amerisourcebergen abc nyseCombination of great tools, asset classes, & low costs - Investopedia